Goldman Sachs analyst Davinthra Thillainathan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ...

Medical device company ResMed (NYSE:RMD) announced in Q4 CY2024, with sales up 10.3% year on year to $1.28 billion. Its non-GAAP profit of $2.43 per share was 5.2% above analysts’ consensus ...

ResMed has been in a holding pattern, posting a small loss of 4.8% while floating around $233.10. The stock also fell short ...

These 2 ASX growth stocks have multiple buy ratings from top brokers as we stroll through 2025. Let's dive in and see.

The stock's fall snapped a two-day winning streak. ResMed Inc. closed 10.21% short of its 52-week high of $263.05, which the company reached on January 30th. Trading volume (2.6 M) eclipsed its 50 ...

ResMed RMD has outperformed the market over the past 10 years by 2.93% on an annualized basis producing an average annual return of 13.86%. Currently, ResMed has a market capitalization of $34.51 ...

ResMed's 10.2% revenue jump in Q2 was driven by strong demand for sleep health products, with a particular focus on expansion in digital health platforms. The 29.3% year-over-year bump up in ...

Brand Evolution Unites Brands Under One Resmed Identity to Make Better Sleep and Breathing Health More Accessible to EveryoneSAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), ...

Shares of ResMed Inc. RMD rallied 1.80% to $236.63 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index SPX falling 2.70% to 5,614.56 and Dow ...

7 out of 10 employed respondents have called in sick at least once ... SAN DIEGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), a global health technology leader focused on sleep, ...